10.19.21 -- Base Your Cryogenic Cold Chain Processes On Cellular Biology, Physics, And Your Patients' Needs
Whatever the stage of your product, getting your cryopreservation and thawing protocols right and managing the risks involved in the sample’s supply chain will help you to bring the right treatment, with the right quality, to the right patient.
Illustrating how mammalian cells change when frozen, Peter Kilbride, senior research scientist, and Julie Meneghel, cryobiologist, offer concrete cryopreservation strategies and identify temperatures at which to stop controlled cooling and transfer drug product to cryogenic storage.
If advanced therapies are to be scaled, their management at hospital sites must be scalable. How can we remove complexity — making life easier for couriers, manufacturers, and hospitals — and create a seamless supply chain?
The cryogenic supply chain for cellular therapies is not without its challenges, destined to increase with scale. Whatever the number of patients you are currently dealing with, considering and addressing these logistics challenges early will help ensure delivering the right treatment, of the necessary quality, at the right time.
We are trying to simplify freezing and thawing protocols, basing them on biology and physics, and it is important to define these final steps to reduce wasting time, effort, and money. Delve into the science of cell thawing.
A “rapid cooling nucleation step” is hypothesized to improve ice nucleation – an important event for good post-thaw outcomes. Explore how a rapid cooling nucleation step affects viable cell count and activity of four cell lines.